Phase II/III trial of BVH 0223 in patients with treatment-resistant affective disorders

Trial Profile

Phase II/III trial of BVH 0223 in patients with treatment-resistant affective disorders

Planning
Phase of Trial: Phase II/III

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Riluzole (Primary)
  • Indications Affective disorders
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2016 According to Biohaven Pharmaceutical media release, company plans to initiate Phase 2/3 studies in 4Q2016 and in 2017.
    • 27 Apr 2016 According to a Biohaven media release, planned initiation date changed from 1 Feb 2016 to 1 Oct 2016.
    • 23 Jul 2015 Data from Phase I trial (see profile 252491) will be used to design this trial, as per a Portage Biotech and Biohaven Pharmaceutical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top